These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 31504033)

  • 21. [Adionuclide therapy for metastatic castration-resistant prostate cancer: New advances].
    Wang SH; Gu YF; Xu S
    Zhonghua Nan Ke Xue; 2023 Mar; 29(3):275-281. PubMed ID: 38597711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elimination of CD4
    Wang C; Chen J; Zhang Q; Li W; Zhang S; Xu Y; Wang F; Zhang B; Zhang Y; Gao WQ
    Cell Res; 2018 Nov; 28(11):1103-1117. PubMed ID: 30297869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer.
    Perner S; Cronauer MV; Schrader AJ; Klocker H; Culig Z; Baniahmad A
    Oncotarget; 2015 Nov; 6(34):35542-55. PubMed ID: 26325261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intermittent Versus Continuous Androgen Deprivation Therapy for Biochemical Progression After Primary Therapy in Hormone-Sensitive Nonmetastatic Prostate Cancer: Comparative Analysis in Terms of CRPC-M0 Progression.
    Salciccia S; Frisenda M; Tufano A; Di Pierro G; Bevilacqua G; Rosati D; Gobbi L; Basile G; Moriconi M; Mariotti G; Forte F; Carbone A; Pastore A; Cattarino S; Sciarra A; Gentilucci A
    Clin Genitourin Cancer; 2024 Apr; 22(2):74-83. PubMed ID: 37758559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Prognostic value of testosterone during androgene deprivation therapy].
    Vallat A; Pillot P; Lebâcle C; Irani J
    Prog Urol; 2019 Sep; 29(10):510-523. PubMed ID: 31311715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resetting the Bar of Castration Resistance - Understanding Androgen Dynamics in Therapy Resistance and Treatment Choice in Prostate Cancer.
    Shore ND; Morgans AK; Ryan CJ
    Clin Genitourin Cancer; 2021 Jun; 19(3):199-207. PubMed ID: 33129718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.
    Harris AE; Metzler VM; Lothion-Roy J; Varun D; Woodcock CL; Haigh DB; Endeley C; Haque M; Toss MS; Alsaleem M; Persson JL; Gudas LJ; Rakha E; Robinson BD; Khani F; Martin LM; Moyer JE; Brownlie J; Madhusudan S; Allegrucci C; James VH; Rutland CS; Fray RG; Ntekim A; de Brot S; Mongan NP; Jeyapalan JN
    Front Endocrinol (Lausanne); 2022; 13():1006101. PubMed ID: 36263323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
    Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
    Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
    [No Abstract]   [Full Text] [Related]  

  • 29. Current Treatment Modalities Targeting Tumor Microenvironment in Castration-Resistant Prostate Cancer.
    Nagireddy S; Qureshi R; Best J; Frech FS; Shah K; Soni Y; Kuchakulla M; Narasimman M; Arora H
    Adv Exp Med Biol; 2021; 1329():295-323. PubMed ID: 34664246
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Fararjeh AS; Liu YN
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31181727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative pathology of dog and human prostate cancer.
    Ryman-Tubb T; Lothion-Roy JH; Metzler VM; Harris AE; Robinson BD; Rizvanov AA; Jeyapalan JN; James VH; England G; Rutland CS; Persson JL; Kenner L; Rubin MA; Mongan NP; de Brot S
    Vet Med Sci; 2022 Jan; 8(1):110-120. PubMed ID: 34628719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
    Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment.
    Anantharaman A; Small EJ
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):625-633. PubMed ID: 28532278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer.
    Semenas J; Dizeyi N; Persson JL
    Drug Des Devel Ther; 2013; 7():875-81. PubMed ID: 24009414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Mechanisms of drug resistance in endocrinotherapy for castration-resistant prostate cancer].
    Bo B; Guo JB; Liu LR; Wei Q
    Zhonghua Nan Ke Xue; 2021 Feb; 27(2):167-171. PubMed ID: 34914335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reconsideration of progression to CRPC during androgen deprivation therapy.
    Mizokami A; Namiki M
    J Steroid Biochem Mol Biol; 2015 Jan; 145():164-71. PubMed ID: 24717975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Leading causes of castration-resistant prostate cancer.
    Lu M; Lu H; Kong Q
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):425-32. PubMed ID: 25645203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway.
    Ardiani A; Gameiro SR; Kwilas AR; Donahue RN; Hodge JW
    Oncotarget; 2014 Oct; 5(19):9335-48. PubMed ID: 25344864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer.
    Chen X; Wu Y; Wang X; Xu C; Wang L; Jian J; Wu D; Wu G
    Eur J Med Res; 2022 Jul; 27(1):105. PubMed ID: 35780240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer.
    Zhang Y; Liao Y; Luo M; Ye Y; Xu Z; Hou W; Liu R; Zhai Q; Lv S; Wei Q
    Prostate; 2023 Nov; 83(15):1446-1457. PubMed ID: 37545197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.